Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorKARAMOUZA, Eleni
dc.contributor.authorGLASSPOOL, Rosalind M.
dc.contributor.authorKELLY, Caroline
dc.contributor.authorLEWSLEY, Liz-Anne
dc.contributor.authorCARTY, Karen
dc.contributor.authorKRISTENSEN, Gunnar B.
dc.contributor.authorETHIER, Josee-Lyne
dc.contributor.authorKAGIMURA, Tatsuo
dc.contributor.authorYANAIHARA, Nozomu
dc.contributor.authorCECERE, Sabrina Chiara
dc.contributor.authorYOU, Benoit
dc.contributor.authorBOERE, Ingrid A
dc.contributor.authorPUJADE-LAURAINE, Eric
dc.contributor.authorRAY-COQUARD, Isabelle
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPROUST LIMA, Cecile
dc.contributor.authorPAOLETTI, Xavier
dc.date.accessioned2023-04-18T08:21:32Z
dc.date.available2023-04-18T08:21:32Z
dc.date.issued2023-03-17
dc.identifier.issn2072-6694en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/173043
dc.description.abstractEn(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients' monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enOvarian cancer
dc.subject.enCA-125
dc.subject.enBiomarker
dc.subject.enLinear mixed model
dc.subject.enMeta-analysis
dc.title.enCA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data
dc.title.alternativeCancers (Basel)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/cancers15061823en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed36980708en_US
bordeaux.journalCancersen_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue6en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamBIOSTAT_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-04072476
hal.version1
hal.date.transferred2023-04-18T08:22:11Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2023-03-17&rft.volume=15&rft.issue=6&rft.eissn=2072-6694&rft.issn=2072-6694&rft.au=KARAMOUZA,%20Eleni&GLASSPOOL,%20Rosalind%20M.&KELLY,%20Caroline&LEWSLEY,%20Liz-Anne&CARTY,%20Karen&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée